Navigation Links
Abbott Wins Top Honor in Wall Street Journal Technology Innovation Awards
Date:9/15/2009

ABBOTT PARK, Ill., Sept. 15 /PRNewswire/ -- Abbott announced today it has been named the overall Gold winner of the 2009 Wall Street Journal Technology Innovation Awards for its Ibis T5000 Biosensor system, which is designed to detect and characterize a broad range of infectious agents in a given sample, including viruses, bacteria and fungi.

"Abbott is dedicated to pursuing innovation to find meaningful solutions that improve lives," said Stafford O'Kelly, head of Abbott's molecular diagnostics business. "This technology represents scientific innovation at its very best, and Abbott is honored to receive this important award."

Abbott's Ibis system (now marketed under the PLEX-ID trade name) was singled out for the top honor, in part, because it promises to alert health officials to new disease strains, and may also guard against bioterrorism and enable hospitals to identify antibiotic-resistant bacteria in its environment.

The Wall Street Journal reports that since the first system was completed in 2005, the technology has "been deployed in 20 sites around the U.S., including the Centers for Disease Control. This spring, the device helped the Naval Health Research Center in San Diego to identify the first two cases of the H1N1 swine flu in the U.S."

The PLEX-ID is a high-throughput technology based on a combination of molecular technologies, including polymerase chain reaction (PCR) and mass spectrometry analysis. The system is designed to address a significant unmet need by providing test results in six to seven hours instead of three or more days as required with current culturing methods.

PLEX-ID is currently intended for research use only and not for use in diagnostic procedures. It is capable of identifying virtually all bacteria, viruses and fungi, and can provide information about drug resistance, virulence and strain type of these agents. Commercial applications for the system include epidemiologic surveillance, monitoring of pandemic diseases, identification of emerging or previously unknown agents, forensic characterization of human samples, identification of sources of hospital-associated infections. Abbott is currently developing the system for human infectious disease diagnostics.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
2. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
3. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
4. Abbott HIV Test Demonstrates Earlier Disease Detection
5. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
6. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
7. Abbott Named One of the Top 10 Companies for Scientists
8. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
9. Abbott to Present at Barclays Global Healthcare Conference
10. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
11. Abbott Announces 11 Percent Increase in Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... today announces publication of a United States multicenter, prospective clinical study that ... disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial and ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology:
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
Breaking Biology News(10 mins):